Justo Ana Sofia da Silva, Nóbrega Sandra Micaela Abreu, Silva Ana Luísa Aires
Faculty of Medicine, University of Porto, Porto, Portugal.
Department of Neurology, Faculty of Medicine, Centro Hospitalar Universitário São João, Porto, Portugal.
J Clin Neurol. 2024 May;20(3):256-264. doi: 10.3988/jcn.2023.0068. Epub 2024 Jan 1.
Undiagnosed atrial fibrillation (AF) is a major risk factor for stroke that can go unnoticed in individuals with embolic stroke of undetermined source (ESUS) or cryptogenic stroke (CS). Early detection is critical for stroke prognosis and secondary prevention. This study aimed to determine if blood biomarkers of myocardial stress can accurately predict AF in patients with ESUS/CS, which would allow the identification of those who would benefit from closer monitoring.
In February 2023 we performed a systematic date-unrestricted search of three databases for studies on patients with ESUS/CS who were subsequently diagnosed with AF. We examined the relationships between AF and serum myocardial stress markers such as brain natriuretic peptide (BNP), N-terminal-pro-BNP (NT-proBNP), midregional proatrial natriuretic peptide, and troponin.
Among the 1,527 studies reviewed, 23 eligible studies involving 6,212 participants, including 864 with AF, were analyzed. A meta-analysis of 9 studies indicated that they demonstrated a clear association between higher NT-proBNP levels and an increased risk of AF, with adjusted and raw data indicating 3.06- and 9.03-fold higher AF risks, respectively. Lower NT-proBNP levels had a pooled negative predictive value of 91.7%, indicating the potential to rule out AF with an 8% false-negative rate.
Further research is required to fully determine the potential of biomarkers for AF detection after stroke, as results from previous studies lack homogeneity. However, lower NT-proBNP levels have potential in ruling out AF in patients with ESUS/CS. Combining them with other relevant biomarkers may enhance the precision of identifying patients who will not benefit from extended monitoring, which would optimize resource allocation and patient care.
未诊断出的心房颤动(AF)是卒中的主要危险因素,在不明来源栓塞性卒中(ESUS)或隐源性卒中(CS)患者中可能未被察觉。早期检测对卒中预后和二级预防至关重要。本研究旨在确定心肌应激的血液生物标志物能否准确预测ESUS/CS患者的AF,这将有助于识别那些能从更密切监测中获益的患者。
2023年2月,我们对三个数据库进行了系统的不限日期检索,以查找关于随后被诊断为AF的ESUS/CS患者的研究。我们研究了AF与血清心肌应激标志物之间的关系,如脑钠肽(BNP)、N末端脑钠肽原(NT-proBNP)、中段心房利钠肽原和肌钙蛋白。
在审查的1527项研究中,分析了23项符合条件的研究,涉及6212名参与者,其中864人患有AF。对9项研究的荟萃分析表明,较高的NT-proBNP水平与AF风险增加之间存在明显关联,调整后数据和原始数据分别表明AF风险高3.06倍和9.03倍。较低的NT-proBNP水平合并阴性预测值为91.7%,表明有潜力以8%的假阴性率排除AF。
由于先前研究结果缺乏同质性,需要进一步研究以充分确定生物标志物在卒中后检测AF的潜力。然而,较低的NT-proBNP水平在排除ESUS/CS患者的AF方面具有潜力。将它们与其他相关生物标志物结合可能会提高识别那些不会从延长监测中获益的患者的准确性,这将优化资源分配和患者护理。